Wells Fargo cut its target for Integra LifeSciences stock to USD 15.00
Published on 10/08/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Integra LifeSciences (ISIN US4579852082) was trading at EUR 11.60 at Lang & Schwarz on October 8, 2026 at 4:00 p.m. CEST, unchanged from EUR 11.60. Markets Insider reported on October 3, 2026 that Wells Fargo cut its price target for Integra LifeSciences from USD 18.00 to USD 15.00 while keeping an Equal Weight rating.
Three dated figures define the reset
On October 2, 2026, Integra launched a proposed USD 600 million seven-year senior secured term loan as part of a refinancing transaction, according to GlobeNewswire.
Also on October 2, 2026, preliminary third-quarter 2026 revenue was guided to USD 410 million to USD 412 million and adjusted earnings per diluted share to USD 0.55 to USD 0.59, according to GlobeNewswire.
The next day, Wells Fargo lowered its target from USD 18.00 to USD 15.00, with analyst Larry Biegelsen attributing 80 percent of the reduction to the July flooding impact, Markets Insider reported.
What does the refinancing change?
The proposed loan is intended to refinance existing debt, extend maturities and support financial flexibility rather than fund a new acquisition. Integra said completion remained subject to market conditions, with the final size, terms and pricing still unsettled, according to GlobeNewswire.
That financing decision sits alongside the reduced fiscal 2026 outlook. Reported revenue guidance moved from USD 1.654 billion to USD 1.695 billion to USD 1.634 billion to USD 1.654 billion, while adjusted earnings per diluted share guidance declined from USD 2.40 to USD 2.50 to USD 2.30 to USD 2.40, according to GlobeNewswire.
October 21 sets the next date
Integra is scheduled to release third-quarter 2026 financial results on October 21, 2026, before the market opens, followed by an 8:30 a.m. ET conference call, according to GlobeNewswire. The results will test whether the Cincinnati recovery plan can offset the lower guidance and the financing burden.
Integra LifeSciences stock was trading at EUR 11.60 at Lang & Schwarz on October 8, 2026 at 4:00 p.m. CEST, unchanged versus the Lang & Schwarz prior close of EUR 11.60. The further course of trading is shown by the continuously updated real-time quote of Integra LifeSciences stock.
Integra LifeSciences stock facts
- Company: Integra LifeSciences Holdings Corporation
- ISIN: US4579852082
- Ticker: IART
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 8, 2026, 4:00 p.m. CEST: EUR 11.60
- Prior close Lang & Schwarz: EUR 11.60
- Market capitalization: USD 1.0 billion as of October 8, 2026
- Sector / Industry: Healthcare / Medical devices
- Index membership: S&P SmallCap 600
- Next earnings date: October 21, 2026
Market context: Market report Nasdaq Composite.
